<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875702</url>
  </required_header>
  <id_info>
    <org_study_id>2021P000517</org_study_id>
    <nct_id>NCT04875702</nct_id>
  </id_info>
  <brief_title>Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout</brief_title>
  <acronym>TRUST</acronym>
  <official_title>Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The TRUST study is a randomized, controlled multicenter study to evaluate the management of&#xD;
      gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine&#xD;
      the most beneficial for a patient-centered gout outcomes, as well as relevant&#xD;
      CV-metabolic-renal endpoints.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2022</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of gout flare</measure>
    <time_frame>baseline to two years of follow up</time_frame>
    <description>number of gout flares occurring during two years of follow-up between the TTT-SU and TTASx groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>baseline to two years of follow up</time_frame>
    <description>SF-36 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Management of Gout</condition>
  <arm_group>
    <arm_group_label>TTT-SU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The participants randomized to the Treat-to-Target-Serum Urate (TTT-SU) group will be counseled about gout, generalized lifestyle and dietary issues and will be provided with a three-month supply of allopurinol as well as a treatment to prophylax against attacks that might occur during the up-titration of urate lowering therapy. Allopurinol dose increases will occur until SU concentrations achieve a target level &lt; 6.0 mg/dL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTASx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to the treat-to-avoid-symptoms (TTASx) group will receive the same education as the TTT-SU group. In addition, they will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone); enough to treat up to six flares over the ensuing three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>For the TTT-SU group: The dose titration algorithm for allopurinol increases every 4 weeks by 100 mg until the target serum urate of 6 mg/dL is reached or a patient requires 800 mg per day of allopurinol. Subjects will require a blood draw for SU every 4 weeks until reaching the target.&#xD;
For the TTASx group: Subjects randomized to the TTASx group will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone) for up to six flares over the ensuing three months. Urate lowering therapy (ULT) will only be offered after the third flare during the trial.</description>
    <arm_group_label>TTASx</arm_group_label>
    <arm_group_label>TTT-SU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiinflammatory Agent for Gout Flare Prophylaxis</intervention_name>
    <description>naproxen, colchicine and/or prednisone as flare prophylaxis</description>
    <arm_group_label>TTASx</arm_group_label>
    <arm_group_label>TTT-SU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        To be eligible to be enrolled in the study, each patient must:&#xD;
&#xD;
        1. Be 18 years or older; 2. Be in a participating primary care practice with at least one&#xD;
        visit in the previous 36 months; 3. Be diagnosed with gout by the 2015 ACR/EULAR criteria,&#xD;
        with 8 or more points on the 2015 ACR/EULAR criteria scoring algorithm; 4. Have experienced&#xD;
        at least one gout flare attributed in the previous 12 months; and 5. Have a baseline&#xD;
        inter-critical serum urate (SU) ≥ 7.0 mg/dL (in the previous 6 months).&#xD;
&#xD;
        -&#xD;
&#xD;
        Candidates who meet any of the following criteria will be excluded from the study:&#xD;
&#xD;
          1. Diagnosis of CKD Stage 3B or worse (eGFR &lt; 45 mL/min/ 1.73 m2) at screening;&#xD;
&#xD;
          2. More than one subcutaneous tophus on clinical examination at screening;&#xD;
&#xD;
          3. Two or more episodes of renal colic in the past 5 years;&#xD;
&#xD;
          4. Unable to provide a written informed consent;&#xD;
&#xD;
          5. ALT &gt; 3 × upper limit of normal (ULN) (within 6 months of entry);&#xD;
&#xD;
          6. Pregnancy, planning pregnancy, or breastfeeding;&#xD;
&#xD;
          7. Taking mercaptopurine (PURINETHOL®) or azathioprine (IMURAN®);&#xD;
&#xD;
          8. Unlikely to survive 2 years because of comorbidities; or&#xD;
&#xD;
          9. Currently taking &gt; 200 mg per day of allopurinol. Patients taking 200 mg or less of&#xD;
             allopurinol daily may participate, provided they meet the eligibility criteria for&#xD;
             flares and current SU, and they have not had a dose escalation in their allopurinol in&#xD;
             the previous 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Hyon Choi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

